Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report

Indian J Ophthalmol. 2021 Oct;69(10):2865-2866. doi: 10.4103/ijo.IJO_1477_21.

Abstract

A central retinal vein occlusion (CRVO) case in a patient developed with sudden blurred vision in some hemifield areas of his left eye, maintaining 20/20 vision 15-days after the COVID-19 vaccination. Initial retinal findings were venous dilation and tortuosity with dispersing dot hemorrhages. Fluorescein angiography (FA) and optical coherence tomography (OCT) confirmed a non-ischemic CRVO diagnosis, and a complete blood panel was requested with average results. An intravitreal steroid dose was applied. A decrease in best-corrected visual acuity (BCVA) (20/30) with more intraretinal hemorrhages was documented. An intravitreal dose of bevacizumab and oral apixaban were added with a final BCVA of 20/20 with decreased hemorrhages. There is no specific causal relationship between COVID-19 vaccines and CRVO. Without previous risk factors and positive treatment response, this case may correlate the first COVID-19 vaccine dose and the event.

Keywords: COVID-19; CRVO; SARS-Cov2; vaccine.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Bevacizumab / adverse effects
  • COVID-19 Vaccines
  • COVID-19*
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Macular Edema* / drug therapy
  • RNA, Messenger
  • Retinal Vein Occlusion* / diagnosis
  • Retinal Vein Occlusion* / drug therapy
  • Retinal Vein Occlusion* / etiology
  • SARS-CoV-2
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vaccination / adverse effects
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • COVID-19 Vaccines
  • RNA, Messenger
  • Bevacizumab